CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Regionalized immune surveillance relies on the concerted efforts of diverse memory T cell
populations. Of these, tissue-resident memory T (TRM) cells are strategically positioned in …

CD8+ tumor-infiltrating lymphocytes with a tissue-resident memory T (T RM) cell phenotype
are associated with favorable prognosis in patients with triple-negative breast cancer …

Tissue-resident memory CD8+ T (Trm) cells mediate potent local innate and adaptive
immune responses and play a central role against solid tumors. However, whether Trm cells …

Toll-like receptor (TLR) agonists demonstrate therapeutic promise as immunological
adjuvants for anticancer immunotherapy. To date, three TLR agonists have been approved …

Adoptive T cell therapies (ACTs) hold great promise in cancer treatment, but low overall
response rates in patients with solid tumors underscore remaining challenges in realizing …

Following their activation and expansion in response to foreign threats, many T cells are
retained in peripheral tissues without recirculating in the blood. These tissue-resident CD8+ …

Tissue-resident memory T cells (TRM) represent a heterogeneous T cell population with the
functionality of both effector and memory T cells. TRM express residence gene signatures …

Long-lived memory CD8+ T cells play important roles in tumor immunity. Studies over the
past two decades have identified four subsets of memory CD8+ T cells-central, effector, stem …

Summary The Aryl hydrocarbon receptor (Ahr) regulates the differentiation and function of
CD4+ T cells; however, its cell-intrinsic role in CD8+ T cells remains elusive. Herein we …